期刊文献+

力比泰联合顺铂治疗30例恶性胸膜间皮瘤的疗效观察 被引量:9

Curative effect of Alimta combined with platinum complexes in the treatment of 20 patients with malignant pleural mesothelioma
暂未订购
导出
摘要 目的:探讨力比泰(培美曲塞)联合顺铂治疗恶性胸膜间皮瘤(MPM)的疗效和毒副作用。方法:30例恶性胸膜间皮瘤患者采用力比泰联合顺铂全身化疗,其中力比泰500mg/m2第一天静脉点滴,顺铂20mg/m2,第1-5天静脉点滴,21天为1周期,一般3-4周期。观察近期疗效、远期疗效、毒副作用、中位缓解期和中位生存期。结果:30例患者中,CR4例,PR13例,SD7例,NC6例。总有效率56.7%(17/30),中位缓解期6.8个月,中位生存期11.9个月,毒副作用:白细胞减少发生率为30%(9/30),III度-Ⅳ度10%(3/30),血小板减少发生率10%(3/30),皮疹发生率30%(9/30),低热发生率20%(6/30),口腔炎发生率为20%(6/30),其它尚包括恶心、呕吐、疲劳、嗜睡和厌食等。所有毒副作用经对症处理和支持治疗后均恢复正常。结论:力比泰联合顺铂治疗恶性胸膜间皮瘤疗效较好,毒副作用较轻,值得临床推广。 Objective: To evaluate the efficacy and toxicity and side effects of malignant pleural mesothelioma (MPM) treated with Alimta ( pemetrexed ) and cisplatin. Methods: Thirty cases of patients with malignant pleural mesothelioma were treated by the systemic chemotherapy combined with cisplatin and Alimta. Alimta was administered at the dose of 500mg/m^2, iv , day 1. Cisplatin 20mg/m^2, iv, day 1 -5, every there weeks. Results: There were 4 complete remission, 13 partial responses,7 no changes,6 progressive diseases. The total efficiency rate was 56.7% (17/30),the median durations of response and survival were 6.8 and 11.9 months respectively. The main toxicity were:neutropenia 30% ,Ⅲ° -Ⅳ° 10% ,thrombocytopenia 10% ,skin rash 30% ,low- grade fever 20% ,stomatitis 20% , the others including nausea, vomiting, fatigue, lethargy and anorexia. All adverse reactions were cured after treatment. Conclusion: Were treated by Alimta(pemetrexed) and cisplatin is effective and with less toxic and side effects in the treatment of malignant pleural mesothelioma.
出处 《现代肿瘤医学》 CAS 2008年第9期1536-1538,共3页 Journal of Modern Oncology
关键词 恶性胸膜间皮瘤 力比泰 顺铂 malignant pleural mesothelioma Alimta cisplatin
  • 相关文献

参考文献9

  • 1上海市肿瘤研究所流行病学研究室.2000年上海市恶性肿瘤发病率[J].肿瘤,2003,23:532-532.
  • 2Butel JS, Lednick JA. Cell and molecular biology of simian virus 40: Implications for human infections and disease [ J]. Natl Cancer Inst, 1999,91(13) :1166 -1167.
  • 3Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma[ J]. Ann Oncol,2004, 15(2) :257 -260.
  • 4美国FDA批准培美曲塞加顺铂联合治疗恶性胸膜间皮瘤[J].世界临床药物,2004,25(4):194-194. 被引量:7
  • 5何声秀,于爱珍,包兴才.多靶向抗叶酸药ALIMTA[J].国外医学(肿瘤学分册),2003,30(4):296-298. 被引量:18
  • 6Thodtmann R, Depenbrock Hblatter RJ. Preliminary results of a phase study with MTA(LY231514) in combination with cisplatin in patients with solid tumors [ J]. Oncol, 1999,26(2) :89 -93.
  • 7Hughes A,Calvert P, Azzabi A, et al. Phase Ⅰ clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma [ J ]. Clin Oncologt, 2002, 20 (16) :3533 -3544.
  • 8Middleton GW, Smith IE, O'Brien ME, et al. Good symptom relief with paliative MVP chemotherapy in malignant mesothelioma [ J]. Ann Oncol, 1998,9 (3) :269 - 273.
  • 9Vogelzang N J, Rusthoven JJ, Symanowski J, et al. Phase Ⅲ study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma[ J]. J Clin Oncol, 2003,21 (14) :2636 -2644.

二级参考文献19

  • 1Pivot X, Raymond E, Laguerre B, et al. Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck[J]. Br J Cancer, 2001, 85(5): 649-655.
  • 2Goldman ID, Zhao R.Molecular, biochemical, and cellular pharmacology of pemetrexed[J]. Semin Oncol, 2002 ,29(6 Suppl 18) :3-17.
  • 3Schultz RM, Patel VF, Worzalla JF, et al. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514[J].Anticancer Res, 1999, 19(1): 437-443.
  • 4Teicher BA, Chen V, Shih C, et al. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografls [ J ]. Clin Cancer Res, 2000, 6(3): 1016-1023.
  • 5Bischof M, Weber KJ, Blatter J, et al. Interaction of pemetrexed disodium (ALIMTA, multitargeted antifolate) and irradiation in vitro[J]. Int J Radiat Oncol Biol Phys, 2002, 52 (5) : 1381-1388.
  • 6Rinaldi DA, Kuhn JG, Burris HA, et al. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation[J].Cancer Chemother Pharmacol, 1999,44(5) :372-380.
  • 7Fos sella FV, Gatzemeier U. Phase I trials of pemetrexed[J]. Semin Oncol, 2002, 29(2 Suppl 5) :8-16.
  • 8Clarke SJ, Abratt R, Geodhals L, et al. Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer[J]. Ann Oncol, 2002,13(5):737-741.
  • 9Rusthoven J, Eisenhaner E, Butts C, et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study[J]. J Clin Oncol, 1999, 17(4) : 1194-1199.
  • 10Manegold C, Von Pawel J, Pirker R, et al. Front-line treatment of advanced non-small cell lung cancer with MTA and cisplatin: a multicenter phase II trial[J]. Ann Oncol, 2000, 11(4):435-440.

共引文献60

同被引文献28

  • 1汪济东,姜庆玲,汪雪原,张扬.NP方案化学治疗为主的综合治疗晚期非小细胞肺癌[J].临床肿瘤学杂志,2004,9(4):411-412. 被引量:5
  • 2陈淅涓,刘英强,花勤亮,姬颖华.国产长春瑞滨联合顺铂治疗晚期非小细胞肺癌的疗效观察[J].中国医师进修杂志,2006,29(1):46-47. 被引量:4
  • 3马晨光,甘北南,张晓华.恶性胸膜间皮瘤的诊断与治疗[J].黑龙江医学,2007,31(2):95-97. 被引量:7
  • 4郝学志,张湘茹,胡兴胜,王彬,赵龙妹,黄镜.培美曲塞治疗19例复发性晚期非小细胞肺癌[J].中国癌症杂志,2007,17(7):575-577. 被引量:35
  • 5Butel JS,Lednick JA.Cell and molecular biology of simian rirus40:Implications for human infections and disease.Natlcancr Inst,1999.91(13):1166-1167.
  • 6Hanna N,Shepherd FA,Fossella FV,et al.Randomized phase Ⅲ trail of pemetrexed versus docetaxel in patients with non-smal lung cancer previously treated with chemotherapy[J].J Clin Oncol,2004,22(9):1194.
  • 7Hanna N,Shepherd FA,Fossella FV,et al.Randonrized phase trial of pemetrexed versus decetaxed in patients with non-small-cell lung cancer previously treated with chemotheraoy[J].J Clin Oncol,2004,22(9):1589-1597.
  • 8上海市肿瘤研究所流行病学研究室.2000年上海市恶性肿瘤发病率[J].肿瘤,2003,23:532-532.
  • 9周际昌.实用肿瘤内科学[M].北京:人民卫生出版社,2005:601~610.
  • 10Manegold C, Gatzemeier U, von Pawel J, et al. Front - line treatment of advancednon - small - cell lung cancer with MTA ( LY231514, pemetrexed disodium, ALIMTA) andcisplatin : a mul- ticenter phase II trial[ J ]. Ann Onco1,2000,11 (4) :435.

引证文献9

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部